Current risk stratification in AML patients is based mainly on cytogenetics and the presence of common genetic aberrations (NPM1, FLT3-ITD, CEBPA, RUNX1, ASXL1, and TP53 mutations) best exemplified in the ELN risk classification system (1). This evidence concerns the gene NPM1 and acute myeloid leukemia.